Initiating and managing basal insulin therapy is complex, with infinite dosing options, frequent adjustments, and the need to modify in the context of other diabetes medications. This curriculum aims to help you overcome provider barriers and address patient barriers to the use of this important therapy. Join us for two Clinical Coffee Breaks and one PrimaryCareNow, hosted by expert faculty who will guide you through several patient cases and offer guideline recommendations and practical communication strategies

Learning Objectives

  • Appraise the clinician barriers that result in therapeutic inertia when initiating and intensifying basal insulin therapy for people with type 2 diabetes
  • Identify patients who could benefit from newer long-acting basal insulins
  • Implement guideline-directed therapy for basal insulin initiation, intensification, and adjustment in various patient scenarios including cases of patients already on multiple anti-hyperglycemic agents
  • Outline communication strategies to overcome patient barriers to insulin use and adherence



Michelle F. Magee, MD, MBBCh, BAO, LRCPSI

MedStar Health Diabetes Institute
Professor of Medicine
Georgetown University School of Medicine
Washington, DC

Jay H. Shubrook, DO, FAAFP, FACOFP

Primary Care Department
Diabetes Services
Touro University College of Osteopathic Medicine
Vallejo, CA

Commercial Supporter

Novo Nordisk Inc.

Education Partner

Pri-Med Institute

Fine Print

The preferred browser is Google Chrome. If using a different browser, such as Safari, Firefox or Edge, make sure you are using the most up-to-date version. Your Internet settings should be set to accept cookies and JavaScript. If cookies and/or JavaScript are disabled, the site may not function properly. A high-speed Internet connection is not required; however, it is recommended for faster download times.

The opinions, ideas, and recommendations expressed in this educational activity are those of the faculty only and are not necessarily endorsed, nor do they necessarily reflect, those of their affiliated institutions, Pri-Med Institute, Pri-Med Institute Advisory Boards and Consultants, or DBC Pri-Med, LLC.

Clinical judgment must guide each clinician in weighing the possible risks, benefits, or contraindications of any diagnostics, interventions or treatments discussed. Clinicians should review manufacturers’ product information and consider these with the recommendations of other authorities when applying the assessment and/or clinical management strategies discussed in this activity to the care of their patients.

Pri-Med Institute Accredited Provider
Pri-Med programs are owned and operated by DBC Pri-Med, LLC, a division of Diversified Communications, Inc. Pri-Med Institute, the accredited division of Pri-Med, is accredited with commendation by the ACCME and approved as a provider of continuing education by the AANP. Pri-Med Institute is the accredited provider for this activity.

Disclosures and Conflict of Interest
Pri-Med Institute requires all individuals in a position to influence educational content for Pri-Med Institute-certified CME activities to disclose relevant personal financial relationships with commercial interests prior to contributing to its educational activities. Pri-Med Institute assesses disclosed relationships and follows a defined process to resolve real or implied conflicts to ensure, to the best of its ability, that all educational content is free of commercial bias. Financial disclosures are listed in the activity syllabus and will also be printed on the slides and announced at the start of each presentation. Pri-Med Institute and Vindico Medical Education staff have no relevant financial relationships to disclose.

Discussion of Off-Label Uses and Investigational Products
During the course of their presentations, the faculty may mention uses of products that have not been approved in the United States for the indication(s) being discussed. All presenters are instructed to notify participants when they are discussing unapproved uses or investigational agents. In addition, specific slides will include notation of the off-label use or investigational agent being discussed. Views presented related to unapproved uses of products are solely those of the presenter(s) and are not endorsed by Pri-Med Institute or DBC Pri-Med, LLC.

Questions? If you have questions about this activity, please email support@pri-med.com or call (877) 477-4633.

Pri-Med Institute educational activities are developed and conducted in accordance with the ACCME's Essential Areas and Policies. It is the mission of Pri-Med Institute to develop and present educational activities that are timely, fair-balanced, scientifically rigorous, and that serve to improve patient outcomes. To that end, we welcome your comments about how to better serve your needs.